November 20, 2015
Press Release

SEKISUI CHEMICAL CO., LTD.
(TSE Code: 4204)

Notice of the Acquisition of Shares in theClinical Diagnostic Reagents Company "EIDIA Co. Ltd."SEKISUI CHEMICAL CO., LTD. (Headquarters: Osaka City, Osaka Prefecture; President: Teiji Koge;
hereinafter called "SEKISUI CHEMICAL") has signed a share transfer agreement with Eisai Co., Ltd.
(Headquarters: Bunkyo-ku, Tokyo; Representative Corporate Officer and CEO: Haruo Naito; hereinafter
called "Eisai") today, to receive all of the shares thus far issued in the 100% Eisai subsidiary EIDIA Co., Ltd.
(Headquarters: Chiyoda-ku, Tokyo; President: Atsushi Saito; hereinafter called "EIDIA"), which
manufactures, imports, and sells clinical diagnostic reagents, clinical analyzers, laboratory reagents, andphysical and chemical equipment.

1. Background
SEKISUI CHEMICAL places its "Diagnostic System" as one of its "Growing 8" businesses that are driving
growth throughout the Sekisui Chemical Group as part of the midterm management plan
"SHINKA!-Advance 2016" (FY2014 to FY2016) in which we are currently involved, and are pouring ourefforts into expanding business in the Life Science fields, including the Diagnostic System business,centering on SEKISUI MEDICAL CO., LTD. (Headquarters: Chuo-ku, Tokyo; President and CEO: HideoTagashira; hereinafter called "SEKISUI MEDICAL").
SEKISUI MEDICAL has hitherto configured a broad partnership with EIDIA from the joint development to
the manufacture and sale of clinical diagnostic reagents.
The diagnostic reagents/ analyzers market size in Japan shows a stable trend of approx. 500 billion yen,and in recent years this trend has increased slightly. Meanwhile, globally, the market is approx. 6 trillion yen,and there are prospects for market expansion concomitant with the economic growth of the emerging
countries.

12. Reasons for Publishing the Shares Acquisition
The incorporation of EIDIA's specific technologies, products, and human resources into the Sekisui
Chemical Group aims to grow the Sekisui Chemical Group's life science fields into a global businesscorpus with a real presence. Specifically, it is expected to manifest the following three effects in particular.

(1) Expansion of the Scale and Content of the Diagnostics Business
Whereas SEKISUI MEDICAL focuses on diagnostics business such as "hyperlipidemia", "hematologicaldisorders", "diabetes", “infectious diseases” and "rheumatism", EIDIA's strengths lie in diagnostic reagentsfor "cancer" and "rheumatism".
SEKISUI MEDICAL not only plans to expand the nature of its business by focusing anew on the "cancer"
diagnostics business, encouraged by the receipt of EIDIA shares, but also plans to further expand its
business by reinforcing its product lineup by focusing on "rheumatism", which is shared by both companies.

(2) Sales Expansion through Reinforcement of Sales Links
SEKISUI CHEMICAL not only has manufacturing and sales bases for diagnostics businesses in America,
Europe, and China through its consolidated subsidiary Sekisui Diagnostics, LLC. and SEKISUI MEDICALTECHNOLOGY (CHINA) LTD., but also has sales companies that handle Sekisui Chemical Group
products in each corner of the globe. After acquiring EIDIA, Sekisui Chemical group intends to expand
sales of EIDIA’s products through its sales routes both in Japan and other countries. In addition, EIDIA
intends to maintain the sales collaboration with Eisai.

(3) Reinforcement of R&D in New Areas
We will promote the prompt marketization of new products and the development of unique reagentsthrough the mutual use of specific technologies unique to both SEKISUI MEDICAL and EIDIA.
Specifically, in addition to developing the diagnostic reagents in the key areas of "cancer" and"rheumatism", we will also pour our energies into the development of new biomarkers.

3. Summary of Subsidiary Company Being Transferred (EIDIA Co., Ltd.)(1) Name: EIDIA Co., Ltd.
(2) Address: 1-10-6 Iwamoto-cho, Chiyoda-ku, Tokyo(3) Representative: President: Atsushi Saito2(4) Principal Business: The manufacture, import, and sale of clinical diagnostic reagents, clinicalanalyzers, laboratory reagents, and physical and chemical equipment(5) Capital: ¥5,262,480,000(6) Establishment: May 1954
(7) Shareholder: Eisai Co., Ltd. 100%
(8) Latest Business Results
Fiscal Year End

March 2013

March 2014

March 2015

Net Assets

12,636 million yen

12,975 million yen

13,321 million yen

Total Assets

15,449 million yen

15,604 million yen

16,244 million yen

Net Sales

6,188 million yen

6,252 million yen6,285 million yen

Operating Income

519 million yen

554 million yen

585 million yen

Ordinary Income

558 million yen

585 million yen

616 million yen

Net Income

320 million yen

333 million yen

345 million yen(9) Website: http://www.eidia.co.jp/

4. Summary of Share Seller(1) Name: Eisai Co., Ltd.
(2) Address: 4-6-10 Koishikawa, Bunkyo-ku, Tokyo(3) Representative: Representative Corporate Officer and CEO: Haruo Naito(4) Principal Business: R&D, manufacturing, sales, import, and export of pharmaceuticals

5. Assigned Price
22,450 million yen

6. Schedule
November 20, 2015: Share transfer agreement signed
December 28, 2015: Scheduled date of share transfer

7. Impact on Business Results
The impact on the consolidated business results of SEKISUI CHEMICAL through the period of March 2016is thought to be negligible, and there are no changes to the consolidated business results forecast
announced on October 29,2015.
3

Reference: Consolidated business forecast for the period (announced October 29,2015) and the previous period
consolidated business results (unit: million yen)
Consolidated Net
Sales
Consolidated BusinessForecasts for the Period(To March 2016)
Consolidated BusinessResults for the PreviousPeriod(To March 2015)

Consolidated
Operating
IncomeConsolidated
Ordinary Income

Net Income Attributable
to Shareholders

1,120,000

90,00089,00058,0001,112,748

85,76487,97852,995

8. Addendum
Approval of the relevant authorities is a condition for the transfer of these shares.

Reference 1: Sekisui Medical Summary(1) Name: SEKISUI MEDICAL CO., LTD.
(2) Address: KDX Nihombashi 313 Building, 13-5, Nihombashi 3-chome, Chuo-ku, Tokyo(3) Representative: President and CEO: Hideo Tagashira(4) Principal Business: Diagnostics Business, Pharmaceuticals & Fine Chemicals Business, ADME & Tox.
Research Business(5) Paid in Capital : 1.275 billion yen(6) Establishment: April 1, 2008 (previous incarnation as Daiichi Pure Chemicals Co., Ltd. established on
July 10, 1947)(7) Shareholder: SEKISUI CHEMICAL CO., LTD. 100%
(8) Sales: 36.7 billion yen (as of March 2015. SEKISUI MEDICAL alone)(9) Website: http://www.sekisuimedical.jp/

Reference (2): Main SEKISUI CHEMICAL Policies in the Field of Life Sciences (Medical) in RecentYears (M&A, etc.)
October 2006: Acquired Daiichi Pure Chemicals Co., Ltd. from Daiichi Pharmaceutical Co., Ltd.
April 2008: SEKISUI CHEMICAL's medical business departments were merged with Daiichi Pure
Chemicals Co., Ltd., and the company name changed to SEKISUI MEDICAL CO.,LTD.

4

August 2008: Acquired US-based in vitro pre-clinical studies contract research organization Xenotech,LLC.
April 2009: Acquired US-based diagnostic business company American Diagnostica Inc.
February 2011: Acquired the diagnostic business from US-based Genzyme Corporation, and not only
established Sekisui Diagnostics, LLC. in the United States, but also started business byestablishing new foundations or acquiring subsidiaries in the UK, Canada, and Germany
April 2012: Merged American Diagnostica Inc. with Sekisui Diagnostics, LLC.

5